Literature DB >> 9007518

Potent inhibition of angiogenesis by wortmannin, a fungal metabolite.

T Oikawa1, M Shimamura.   

Abstract

Wortmannin ([1S-(1 alpha, 6b alpha, 9a beta, 11 alpha, 11b beta)]-11-(acetyloxy)-1,6b,7,8,9a,10,11,11b-octahydro-1- (methoxymethyl)-9a, 11b-dimethyl-3 H-furo[4,3,2-de]indeno[4,5-h]-2-benzopyran-3,6,9-trione), a fungal metabolite that is as a selective inhibitor of phosphatidylinositol 3-kinase, was evaluated for its potential as an inhibitor of in vivo angiogenesis in a bioassay system involving growing chick embryo chorioallantoic membranes. It showed dose-dependent inhibitory activity against embryonic angiogenesis. This inhibition occurred at a dose as low as 1 ng (2.3 pmol) per egg and the ID50 value was 30 ng/egg. These findings suggest that wortmannin is a new angiogenesis inhibitor, and that it may be a lead antibiotic for a novel class of therapeutic agents for angiogenesis-dependent diseases like cancer, diabetic retinopathy and rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9007518     DOI: 10.1016/s0014-2999(96)00864-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide.

Authors:  W Zundel; L M Swiersz; A Giaccia
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.

Authors:  A Papapetropoulos; G García-Cardeña; J A Madri; W C Sessa
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

3.  A wortmannin-cetuximab as a double drug.

Authors:  R Adam Smith; Hushan Yuan; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

4.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Authors:  J Kang; P G Rychahou; T A Ishola; J M Mourot; B M Evers; D H Chung
Journal:  Oncogene       Date:  2008-02-18       Impact factor: 9.867

5.  Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.

Authors:  Deepak Sampath; Jason Oeh; Shelby K Wyatt; Tim C Cao; Hartmut Koeppen; Jeffrey Eastham-Anderson; Liliane Robillard; Calvin C K Ho; Jed Ross; Guanglei Zhuang; Hani Bou Reslan; Philip Vitorino; Kai H Barck; Sharon E Ungersma; Jean Michel Vernes; Maresa Caunt; Nick Van Bruggen; Weilan Ye; Ulka Vijapurkar; Yu-Ju Gloria Meng; Napoleone Ferrara; Lori S Friedman; Richard A D Carano
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

6.  The antiproliferative cytostatic effects of a self-activating viridin prodrug.

Authors:  Adam Smith; Joseph Blois; Hushan Yuan; Elena Aikawa; Christian Ellson; Jose-Luiz Figueiredo; Ralph Weissleder; Rainer Kohler; Michael B Yaffe; Lewis C Cantley; Lee Josephson
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

Review 7.  Targeting of proangiogenic signalling pathways in chronic inflammation.

Authors:  Sander W Tas; Chrissta X Maracle; Emese Balogh; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543

Review 8.  Nitric oxide signaling during myocardial angiogenesis.

Authors:  Takahisa Kondo; Koichi Kobayashi; Toyoaki Murohara
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

9.  A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.

Authors:  M Shimamura; H Nagasawa; H Ashino; Y Yamamoto; T Hazato; Y Uto; H Hori; S Inayama
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

10.  An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.

Authors:  Witold W Kilarski; Ludvig Petersson; Peder Fredlund Fuchs; Marcin S Zielinski; Pär Gerwins
Journal:  Angiogenesis       Date:  2012-08-24       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.